These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 35003132)

  • 1. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
    Nakagawa T; Tanino T; Onishi M; Tofukuji S; Kanazawa T; Ishioka Y; Itoh T; Kugimiya A; Katayama K; Yamamoto T; Nagira M; Ishii KJ
    Front Immunol; 2021; 12():803090. PubMed ID: 35003132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
    Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
    Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.
    Hayashi T; Momota M; Kuroda E; Kusakabe T; Kobari S; Makisaka K; Ohno Y; Suzuki Y; Nakagawa F; Lee MSJ; Coban C; Onodera R; Higashi T; Motoyama K; Ishii KJ; Arima H
    Front Immunol; 2018; 9():2619. PubMed ID: 30515151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis.
    Zonneveld-Huijssoon E; van Wijk F; Roord S; Delemarre E; Meerding J; de Jager W; Klein M; Raz E; Albani S; Kuis W; Boes M; Prakken BJ
    Ann Rheum Dis; 2012 Oct; 71(10):1706-15. PubMed ID: 22562976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
    Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
    Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
    Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
    J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.
    Liu C; Chu X; Sun P; Feng X; Huang W; Liu H; Ma Y
    Hum Vaccin Immunother; 2018 Apr; 14(4):931-940. PubMed ID: 29271696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
    Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
    J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines.
    Zhang TT; Kang TH; Ma B; Xu Y; Hung CF; Wu TC
    Vaccine; 2012 Jan; 30(4):784-93. PubMed ID: 22120194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
    Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
    Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
    Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer.
    Wang HL; Xu H; Lu WH; Zhu L; Yu YH; Hong FZ
    Arch Gynecol Obstet; 2014 Jan; 289(1):155-62. PubMed ID: 23912529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model.
    Kim TG; Kim CH; Won EH; Bae SM; Ahn WS; Park JB; Sin JI
    Immunology; 2004 May; 112(1):117-25. PubMed ID: 15096191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
    Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
    Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
    Karan D; Krieg AM; Lubaroff DM
    Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine.
    Liu TY; Hussein WM; Giddam AK; Jia Z; Reiman JM; Zaman M; McMillan NA; Good MF; Monteiro MJ; Toth I; Skwarczynski M
    J Med Chem; 2015 Jan; 58(2):888-96. PubMed ID: 25489968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.